View the video below to hear from Dr Naomi Allen on the UK Biobank biomarker panel.
A Timeline for future data availability can be found here.
In order to enhance further the value of the UK Biobank resource to researchers, UK Biobank is measuring a wide range of biochemical markers from biological samples collected at baseline in all 500,000 participants.
The biomarkers selected for assay have been chosen because they are established risk factors for disease (e.g., lipids for vascular disease, sex hormones for cancer), diagnostic measures (e.g., HbA1c for diabetes and rheumatoid factor for arthritis) or characterize phenotypes not otherwise well assessed (e.g., biomarkers for renal and liver function).
UK Biobank’s Enhancements Working Group has been responsible for developing the present panel following extensive consultation with relevant experts to identify biomarkers that are likely to be of most scientific relevance for studying a wide range of diseases.
The biomarkers are being measured in UK Biobank’s purpose-built facility in Stockport using the most up-to-date analytical methods that are available.